JNJ Stock: Johnson & Johnson — Profile, Analysis & Investor Guide (2026)
The world’s premier healthcare giant specializing in innovative medicine and MedTech solutions — Updated June 2026 with current price, P/E ratio, analyst ratings, financials, and investor insights.
Johnson & Johnson (JNJ) remains a cornerstone of the global healthcare landscape, having successfully transitioned into a leaner, high-growth entity following the spin-off of its consumer health division, Kenvue. Now focused exclusively on Innovative Medicine (Pharmaceuticals) and MedTech (Medical Devices), the company leverages one of the world’s most robust R&D pipelines. While aggressive investors might seek higher volatility in sectors found on the Small Cap Aerospace & Defense Stocks list, JNJ provides a bedrock of stability with an enviable AAA credit rating.
As a designated Dividend King with over 60 years of consecutive payout increases, Johnson & Johnson is often a primary holding for those building long-term wealth. Its defensive nature makes it a popular alternative for investors who want to balance out more cyclical holdings like those in the Complete List Of Food & Beverage Companies Listed On U.S. Exchanges or even high-energy assets like professional sports ownership, as seen in the List Of Publicly Traded Sports Companies. In 2026, the company continues to navigate legal resolutions while expanding its surgical robotics and oncology portfolios.
Key Takeaways — JNJ Stock
With over 60 years of dividend increases, JNJ is a premier choice for reliable income, supported by a healthy payout ratio and strong cash flow.
JNJ is one of only two U.S. companies with a credit rating higher than the U.S. federal government, signaling extreme financial stability.
The MedTech segment is seeing double-digit growth driven by electrophysiology, surgical robotics, and orthopedic innovations.
Ongoing talc-related legal settlements are moving toward a comprehensive resolution, potentially removing a major long-term overhang on the stock.
JNJ Stock Health Score
Scores out of 10 based on current fundamentals, valuation, momentum and income data.
JNJ — Live Stock Chart
Real-time price chart powered by TradingView.
JNJ — Key Statistics & Valuation
Core financial data as of June 2026.
| Valuation | Value | Financials | Value |
|---|---|---|---|
| Market Cap | $574.10B | Revenue (TTM) | $96.36B |
| P/E Ratio (TTM) | 27.45 | Net Income | $26.80 billion |
| Forward P/E | 20.08 | EPS (TTM) | $8.64 |
| Price/Sales | 5.96 | Gross Margin | 68.04% |
| Price/Book | 7.24 | Net Margin | 21.83% |
| PEG Ratio | 2.15 | ROE | 26.42% |
| Beta | 0.26 | Debt/Equity | 0.48 |
| 52-Week High | $251.71 | 52-Week Low | $149.04 |
| Avg Daily Volume | 7.61 million | YTD Return | 13.44% |
| 1-Year Return | 53.51% | 5-Year Return | 36.80% |
| Dividend Yield | 2.31% | Payout Ratio | 44.20% |
| Analyst Rating | Buy | Price Target | $252.87 |
| Sector | Healthcare | Industry | Drug Manufacturers General |
| CEO | Joaquin Duato | Employees | 138,200 |
| Founded | January 1886 | Headquarters | New Brunswick, New Jersey, US |
JNJ — Business Overview
Highly specialized drugs for oncology and immunology alongside medical devices for surgery, vision care, and orthopedics.
Revenue is split between the Innovative Medicine segment (pharmaceuticals) and MedTech, primarily through global healthcare provider sales.
A massive R&D budget combined with a globally integrated supply chain and unparalleled brand trust among clinicians.
Expansion of the DARZALEX oncology franchise and the integration of acquired MedTech assets like Abiomed and Shockwave Medical.
JNJ — Financial Performance Snapshot
| 📈 Growth | Value | 📊 Profitability | Value | 🎯 Valuation | Value |
|---|---|---|---|---|---|
| Revenue Growth YoY | 5.50% | Gross Margin | 68.04% | P/E Ratio | 27.45 |
| EPS Growth YoY | 7.20% | Net Margin | 21.83% | Forward P/E | 20.08 |
| 5Y Revenue CAGR | 4.85% | ROE | 26.42% | PEG Ratio | 2.15 |
| Free Cash Flow | $18.4B | Operating Margin | 28.15% | Price/Sales | 5.96 |
JNJ — Analyst Ratings & Price Target
Based on 21 analysts covering JNJ as of June 2026.
High: $285.00 | Low: $220.00 | Upside from current: 6.03%
14 Buy | 6 Hold | 1 Sell ratings from covering analysts.
Morgan Stanley maintained a Buy rating following strong quarterly earnings from the MedTech segment.
JNJ Technical Analysis
Real-time buy/sell signals from TradingView.
JNJ — Pros & Cons
✓ Defensive Powerhouse
Extremely low beta (0.26) makes it one of the best “all-weather” stocks during market volatility.
✗ Legal Liabilities
Talcum powder litigation continues to be a multi-billion dollar financial and reputational risk.
✓ Robust R&D Pipeline
Consistent investment in new therapeutic areas keeps them ahead of the patent cliff curve.
✗ High P/E Ratio
Currently trading at a higher premium than its historical average, limiting immediate upside.
✓ MedTech Integration
The recent focus on high-growth device technologies is diversifying revenue beyond drugs.
✗ Patent Expirations
Key drugs like Stelara face biosimilar competition, requiring new blockbusters to fill the gap.
Who Should Consider JNJ?
Conservative investors looking for a “sleep-well-at-night” stock with reliable dividend income.
Growth-focused traders seeking rapid, short-term capital gains or high-beta tech exposure.
Long-term (5-10+ years) to benefit from dividend compounding and the multi-year drug development cycle.
Highly suitable for tax-advantaged accounts like IRAs due to its significant dividend payout.
JNJ vs Competitors
| Company | Ticker | Market Cap | P/E | Rev Growth | Net Margin | Dividend | 1Y Return |
|---|---|---|---|---|---|---|---|
| Johnson & Johnson ★ | JNJ | $574.10B | 27.45 | 5.50% | 21.83% | 2.31% | 53.51% |
| Pfizer | PFE | $165.20B | 12.40 | 3.10% | 15.20% | 5.40% | -8.20% |
| Merck | MRK | $325.40B | 18.90 | 6.80% | 18.50% | 2.45% | 14.10% |
| AbbVie | ABBV | $305.10B | 22.10 | 4.20% | 19.10% | 3.15% | 11.40% |
JNJ — Key Risks
Talc and Opioid Litigation
While the company has reserves, the final cost of settling decades of litigation remains uncertain and could impact margins.
Biosimilar Competition
As patents for key drugs expire, cheaper competitors enter the market, putting pressure on top-line revenue growth.
Medicare Price Negotiations
The Inflation Reduction Act’s impact on drug pricing could limit the profitability of high-margin medications in the U.S.
Integration Execution
Recent multi-billion dollar acquisitions in the MedTech space must be successfully integrated to achieve projected growth targets.